Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion

BACKGROUND: Alectinib and crizotinib have been approved as first-line therapies for advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene fusion. However, the therapeutic efficacy and side effects are still largely unknown of patients who switched to next-generation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Transl Med
Main Authors: Pan, Yingying, Xiao, Wenjing, Ye, Feng, Wang, Huijuan, Shen, Yihong, Yu, Xinmin, Han, Xiao, Chu, Qian, Zhou, Caicun, Zhang, Zhihong, Ren, Shengxiang
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8267309/
https://ncbi.nlm.nih.gov/pubmed/34277814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-21-2769
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados